Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Armstrong Albuterol Sulfate Inhalation Aerosol
Amphastar France Pharmaceuticals
Asthma
1 trial -
MYCOPHENOLATE MOFETIL, ETOPOSIDE, DURVALUMAB, INFLIXIMAB, SILTUXIMAB, Tarlatamab, CARBOPLATIN, Tarlatamab
Amgen
Extensive stage small cell lung cancer (ES-SCLC). Small-cell lung cancer, accounting for 10% to 15% of lung cancer (Rudin et al, 2015), is an aggressive lung cancer subtype with neuroendocrine differentiation and strongly associated with smoking (Koinis et al, 2016). It displays a distinct natural history characterized by a high growth fraction, rapid doubling time and early establishment of widespread metastatic lesions (Gustafsson et al, 2008). Around 70% of patients are diagnosed with ES-SCLC, presenting with distant metastasis or tumor or nodal volume that is too large to be encompassed in a tolerable radiation plan.
1 trial -
albuterol (Armstrong Albuterol HFA)
Amphastar France Pharmaceuticals
Asthma
1 trial -
albuterol HFA (Armstrong's)
Amphastar France Pharmaceuticals
Asthma
1 trial -
Evolution: Young Women Taking Charge and Growing Stronger
BRIGHT MINDS BIOSCIENCES INC.
HIV
1 trial -
IVERMECTIN
The George Institute
Strongyloidiasis is caused by a parasite that is globally distributed in tropical and sub-tropical areas. Most patients with strongyloidiasis are asymptomatic or have mild symptoms with gastrointestinal disturbances, respiratory symptoms, and skin lesions. In situations of low defenses (patients under treatment with corticosteroids, organ transplant recipients or other situations) they can present serious complications with high mortality.
1 trial -
A SINGLE-CENTER, OPEN-LABEL, TWO-PERIOD STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE ITRACONAZOLE, A STRONG CYP3A INHIBITOR, ON THE PHARMACOKINETICS OF A SINGLE 30 MG DOSE OF RO7269162 IN HEALTHY PARTICIPANTS
Hoffmann-La Roche
Not applicable, healthy volunteers
1 trial -
Rongliflozin
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Type 2 Diabetes Mellitus
1 trial -
[14C]- Rongliflozin
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Healthy Adult Male Volunteers
1 trial -
pyroglutamate rongliflozin capsules
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Diabetes Mellitus, Type 2
1 trial -
pyroglutamate rongliflozin capsules
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Type 2 Diabetes
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources